Careers
Secretome Therapeutics is a clinical-stage cell therapy company focused on orphan and underserved cardiac diseases. STM-01, the lead drug, is a neonatal cardiac progenitor cell (nCPC) isolated from cardiac tissue excised during life-saving, open-heart surgery on newborns with congenital heart defects. The main target indication for STM-01 is Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM).